On November 1, 2019, the USFDA issued an update containing the latest information of Ranitidine. Concluding from the results provided by the USFDA, Strides Pharma’s Ranitidine Tablets 300 mg (Rx) are within acceptable limits for NDMA of 96 nanograms per day or 0.32 ppm.